: Hit Wegovy weight-loss drug on track for $4 billion in U.S. sales despite supply constraints, analyst says

The hit Wegovy weight-loss drug is on track for sales of over $4 billion this year in the U.S. alone, despite its manufacturer Novo Nordisk struggling to keep up with demand.

Previous post Financial News: UBS faces hundreds of millions in fines over Credit Suisse’s Archegos: report
Next post ‘The Flash,’ ‘Elemental’ disappoint as ‘Spider-Verse’ continues box office domination